Zhengye Biotechnology Holding Limited
ZYBTHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 21, 2026
Scan Results
Daily timeframeZhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company carries a $379.6M market cap, placing it firmly in the small-cap category. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Market Cap
$379.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.76
EPS (Fwd)
—
ROE
-25.2%
ROA
-9.5%
Cash
$51.9M
Total Debt
$75.1M
Free CF
$39.6M
52W Change
-87.7%
Annual Financials
Cash vs Debt
Zhengye Biotechnology Holding Limited carries $75.1M in total debt against $51.9M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $39.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -25.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $260.3M (2022) to $116.4M (2025), a 55% decline worth watching.
Investors considering Zhengye Biotechnology Holding Limited should weigh the typical risks associated with ZYBT's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZYBT.